We have located links that may give you full text access.
Journal Article
Review
Are there any realistic chances to develop new drugs for asthma?
Drug News & Perspectives 2006 May
Asthma bronchiale, an inflammatory airway disease, imposes a significant health care problem worldwide. It is characterized by three critical phenotypic traits: intermittent and reversible bronchoconstriction, bronchial hyperresponsiveness and airway inflammation. Conventional therapy basically consists of beta(2)-adrenoceptor agonists in combination with glucocorticoids. Nevertheless, there is an urgent need for novel therapies, both for patients with uncontrollable disease symptoms and for those suffering from glucocorticoid-insensitive asthma. Monotherapy seems to be relatively ineffective against this complex and multifaceted disease, which is evident by the variety of disappointing treatment strategies. Thus, we should instead concentrate on multiple target strategies, such as novel and more potent glucocorticoids or phosphodiesterase type 4 (PDE4) inhibitors with isozyme selectivity. In addition, an examination of the application method should not be neglected, with emphasis on inhalative approaches. To summarize, research into asthma's pathophysiology is of critical importance, concentrating on human-relevant targets and conducting preliminary studies. With these imperatives in mind, we can hope to better manage this multifactor disease in the near future.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app